• 16 Apr, 2026
Gland Pharma Brings Back Naina Lal Kidwai as Independent Director for Another 5 Years

Gland Pharma Brings Back Naina Lal Kidwai as Independent Director for Another 5 Years

In the fast paced world of Indian pharmaceuticals, strong leadership are not just nice to have they are essential for long term success. On April 9, 2026 Gland Pharma Limited made a strategic announcement that reinforces exactly that: re appointment of Naina Lal Kidwai, a trailblazing banker and seasoned board leader, as Independent Director for a second consececutive five year term.

Shocking Rajasthan Drug Alert: Qcepod 200 Contains No Antibiotic

In a shocking development that has sent ripples across India’s pharmaceutical landscape, Rajasthan’s drug control authorities have issued a statewide alert over a popular antibiotic. Laboratory tests revealed that a widely distributed batch of Qcepod 200 (Cefpodoxime Proxetil 200 mg tablets) contained no active ingredient at all.

Read More

Cipla Leadership Transition 2026: Umang Vohra Steps Down, New MD and Global CEO Appointed as Achin Gupta Takes the Helm

In the fast paced world of Indian pharmaceuticals, leadership changes can signal big shifts in strategy and growth. Today, Cipla Limited one of India’s most respected drugmakers officially entered a new chapter. Following a Board meeting on March 30, 2026 company announced that long time Managing Director and Global CEO Umang Vohra has stepped down effective April 1, 2026.

Read More

Eluru: B.Pharma Student Suicide After Farewell Party

A third year B.Pharma student named Ch. Suvarshini lost her life after jumping from the hostel building at SIR CR Reddy College of Pharmaceutical Science. This incident occurred shortly after a farewell party where she was allegedly forced to dance and teased by friends. She spoke to her family before the fall and she was immediately rushed to hospital but could not be saved.

Read More

JB Pharma Hit with ₹80.81 Lakh GST Penalty

JB Pharma has been hit with a ₹80.81 lakh GST penalty, raising questions about tax compliance in the pharma industry. What led to this action, and should investors be concerned? Here’s a complete breakdown of the case and its implications.

Read More